- Home
- EVOK vs APM Comparison
EVOK vs APM Comparison
Compare EVOK & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- APM
- Stock Information
- Founded
- EVOK 2007
- APM 2010
- Country
- EVOK United States
- APM United Kingdom
- Employees
- EVOK N/A
- APM N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- APM Health Care
- Exchange
- EVOK Nasdaq
- APM Nasdaq
- Market Cap
- EVOK 7.7M
- APM 6.9M
- IPO Year
- EVOK 2013
- APM 2018
- Fundamental
- Price
- EVOK $4.43
- APM $1.81
- Analyst Decision
- EVOK
- APM
- Analyst Count
- EVOK 0
- APM 0
- Target Price
- EVOK N/A
- APM N/A
- AVG Volume (30 Days)
- EVOK 7.2M
- APM 10.1M
- Earning Date
- EVOK 08-12-2025
- APM 08-05-2025
- Dividend Yield
- EVOK N/A
- APM N/A
- EPS Growth
- EVOK N/A
- APM N/A
- EPS
- EVOK N/A
- APM N/A
- Revenue
- EVOK $11,594,083.00
- APM N/A
- Revenue This Year
- EVOK $57.82
- APM N/A
- Revenue Next Year
- EVOK $59.12
- APM N/A
- P/E Ratio
- EVOK N/A
- APM N/A
- Revenue Growth
- EVOK 89.89
- APM N/A
- 52 Week Low
- EVOK $1.94
- APM $0.46
- 52 Week High
- EVOK $12.32
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- EVOK 53.72
- APM 64.19
- Support Level
- EVOK $4.26
- APM $1.40
- Resistance Level
- EVOK $4.73
- APM $1.97
- Average True Range (ATR)
- EVOK 0.73
- APM 0.41
- MACD
- EVOK -0.07
- APM 0.07
- Stochastic Oscillator
- EVOK 25.95
- APM 26.69
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.